Hyperlipidaemia News

  • 26 November 2020
    This report discusses this phenotypic cascade screening program, much needed in South Africa. Familial hypercholesterolaemia (FH, inherited high cholesterol) is one of the commonest inherited diseases in the world, affecting about one in 250 to 300 of White populations (1). However, some countries such as South Africa have a higher prevalence (1:...
  • 23 November 2020
    Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Prof Alan Remaley  The post LDL-cholesterol: “The times are a-changin” appeared first on PCSK9 Forum.
  • 20 November 2020
    Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Dr Joe Witztum  The post Keynote – Lipoprotein(a): “The proof of the pudding is in the trial” appeared first on PCSK9 Forum.
  • 18 November 2020
    The post VIDEO: Evinacumab in refractory hypercholesterolaemia appeared first on PCSK9 Forum.
  • 17 November 2020
    Benefit from alirocumab does not depend on triglyceride levels Are triglyceride (TG) levels associated with the risk for recurrent cardiovascular events in acute coronary syndrome (ACS) patients? Findings from this analysis from ODYSSEY OUTCOMES support baseline TG levels as an independent predictor of major adverse cardiovascular events (MACE) in...
  • 17 November 2020
    AZD8233: a potent PCSK9 synthesis inhibitor Data from a ‘first in human’ study suggest potential for AZD8233, a novel antisense oligonucleotide (1). This agent employs linkage with N-acetyl galactosamine (GalNAc) for efficient targeting of PCSK9 mRNA in hepatocytes to prevent the synthesis of PCSK9. In a randomized, single-blind, placebo-...
  • 17 November 2020
    Evolocumab highly effective in patients with prior PCI Patients with atherosclerotic cardiovascular disease (ASCVD) and a history of percutaneous coronary intervention (PCI) are at very high risk for cardiovascular events. These individuals also benefit substantially from treatment with evolocumab on top of statin, as demonstrated in this analysis...
  • 17 November 2020
    Evinacumab, a fully human monoclonal antibody inhibitor of angiopoietin-like 3 protein (ANGPTL3), given either intravenously or subcutaneously, more than halved LDL cholesterol when given on top of statin, ezetimibe and a PCSK9 inhibitor in patients with refractory hypercholesterolaemia. Earlier this year, evinacumab (15 mg/kg intravenously (IV)...
  • 17 November 2020
    News from AHA 2020 Virtual: Professor Steve Nicholls (Monash University, Melbourne, Australia) puts the STRENGTH results in context (lead-in video: Prof. Steve Nicholls discusses STRENGTH) The post VIDEO: Prof Steve Nicholls discusses STRENGTH appeared first on PCSK9 Forum.
  • 17 November 2020
    News from AHA 2020 Virtual: Professor Steve Nicholls (Monash University, Melbourne, Australia) discusses fish oils and risk for atrial fibrillation and implications for clinical practice (lead-in for video Prof. Steve Nicholls – fish oils and AF) The post VIDEO: Prof Steve Nicholls fish oils and AF appeared first on PCSK9 Forum.
  • 17 November 2020
    Final results from STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia) not only show lack of cardiovascular benefit with this carboxylic acid omega-3 formulation in statin-treated patients with elevated triglycerides, but also highlight a potential safety...
  • 13 November 2020
    In the primary prevention setting, individuals aged 75 years or older with elevated LDL cholesterol are at higher absolute cardiovascular risk than those who are younger. These people would gain from lipid lowering treatment, which is as efficacious as in younger age groups. These are the key messages from two studies published in The Lancet (1,2...
  • 13 November 2020
    The post VIDEO: Do we treat high LDL-C in the ‘healthy’ elderly? appeared first on PCSK9 Forum.
  • 13 November 2020
    Prof Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) discusses the latest evidence on this contentious question. Atherosclerosis is a progressive disease in which LDL cholesterol is a major driver. Supported by incontrovertible evidence that LDL is causal for atherosclerotic cardiovascular disease (ASCVD)(1,2), current...
  • 30 October 2020
    Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Dr. Kirsten Bibbins-Domingo & Prof. Dhruv S. Kazi  The post Cost-effectiveness of PCSK9 inhibitors: A coming of age? appeared first on PCSK9 Forum.
  • 23 October 2020
    Lipoprotein(a) lowering contributed to total cardiovascular event reduction in acute coronary syndrome (ACS) patients independent of the effects of alirocumab on LDL cholesterol, according to this analysis of ODYSSEY OUTCOMES. The ODYSSEY OUTCOMES trial previously reported that lowering lipoprotein(a) [Lp(a)] with alirocumab reduced the risk of...
  • 22 October 2020
    The post Prof. Gilles Montalescot – Key questions appeared first on PCSK9 Forum.
  • 21 October 2020
    Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Gregory Schwartz  The post A target level for LDL-C in secondary prevention: What have we learned from PCSK9 inhibitor trials? appeared first on PCSK9 Forum.
  • 21 October 2020
    Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor John Chapman  The post LDL subclasses, bioactive lipids and atherogenicity: Impact of statin action appeared first on PCSK9 Forum.
  • 21 October 2020
    Reports from the 13th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor Gilles Montalescot  The post COVID-19 infection and cardiovascular events appeared first on PCSK9 Forum.

Pages